{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T22:50:37Z","timestamp":1794091837279,"version":"4.8.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Colorectal cancer (CRC) is one of the most common malignant tumors worldwide and understanding its underlying molecular mechanisms is crucial for the development of therapeutic strategies. The mitogen-activated protein kinase-kinase 3 (MKK3) is a specific activator of p38 MAP kinases (p38 MAPKs), which contributes to the regulation of several cellular functions, such as proliferation, differentiation, apoptosis as well as response to drugs. At present, the exact MKK3\/p38 MAPK pathway contribution in cancer is heavily debated because of its pleiotropic function. In this work, we retrospectively explored the prognostic and pathobiologic relevance of MKK3 in a cohort of CRC patients and assessed MKK3 molecular functions in a panel of CRC lines and colonocytes primary cultures. We found increased MKK3 levels in late-stage CRC patients which correlated with shorter overall survival. Herein, we report that the MKK3 targeting by inducible RNA interference univocally exerts antitumor effects in CRC lines but not in primary colonocytes. While MKK3 depletion per se affects growth and survival by induction of sustained autophagy and death in some CRC lines, it potentiates response to chemotherapeutic drug 5-fluorouracil (5-FU) in all of the tested CRC lines in vitro. Here, we demonstrate for the first time that in CRC the MKK3 specifically activates p38delta MAPK isoform to sustain prosurvival signaling and that such effect is exacerbated upon 5-FU challenge. Indeed, p38delta MAPK silencing recapitulates MKK3 depletion effects in CRC cells in vitro and in vivo. Overall, our data identified a molecular mechanism through which MKK3 supports proliferation and survival signaling in CRC, further supporting MKK3 as a novel and extremely attractive therapeutic target for the development of promising strategies for the management of CRC patients.<\/jats:p>","DOI":"10.1038\/s41419-019-2083-2","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T02:03:33Z","timestamp":1573092213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["MKK3 sustains cell proliferation and survival through p38DELTA MAPK activation in colorectal cancer"],"prefix":"10.1038","volume":"10","author":[{"given":"Lorenzo","family":"Stramucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Pranteda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Stravato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Azzurra","family":"Amoreo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Pennetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Diodoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Bartolazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2947-1063","authenticated-orcid":false,"given":"Gianluca","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"2083_CR1","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.2174\/1381612822666160304151011","volume":"22","author":"LS Steelman","year":"2016","unstructured":"Steelman, L. S. et al. Critical roles of EGFR family members in breast cancer and breast cancer stem cells: targets for therapy. Curr. Pharm. Des. 22, 2358\u20132388 (2016).","journal-title":"Curr. Pharm. Des."},{"key":"2083_CR2","doi-asserted-by":"publisher","unstructured":"Hall, M. J., Morris, A. M. & Sun, W. Precision medicine versus population medicine in colon cancer: from prospects of prevention, adjuvant chemotherapy, and surveillance. Am. Soc. Clin. Oncol. Educ. Book 220\u2013230, https:\/\/doi.org\/10.1200\/EDBK_200961 (2018).","DOI":"10.1200\/EDBK_200961"},{"key":"2083_CR3","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1126\/science.7839144","volume":"267","author":"B D\u00e9rijard","year":"1995","unstructured":"D\u00e9rijard, B. et al. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 267, 682\u2013685 (1995).","journal-title":"Science"},{"key":"2083_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18632\/aging.100878","volume":"8","author":"G Bossi","year":"2016","unstructured":"Bossi, G. MKK3 as oncotarget. Aging (Albany NY) 8, 1\u20132 (2016).","journal-title":"Aging (Albany NY)"},{"key":"2083_CR5","doi-asserted-by":"publisher","first-page":"e84818","DOI":"10.1371\/journal.pone.0084818","volume":"9","author":"DL Boyle","year":"2014","unstructured":"Boyle, D. L. et al. Differential roles of MAPK kinases MKK3 and MKK6 in osteoclastogenesis and bone loss. PLoS ONE 9, e84818 (2014).","journal-title":"PLoS ONE"},{"key":"2083_CR6","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.cellsig.2009.11.020","volume":"22","author":"G Remy","year":"2010","unstructured":"Remy, G. et al. Differential activation of p38MAPK isoforms by MKK6 and MKK3. Cell Signal 22, 660\u2013667 (2010).","journal-title":"Cell Signal"},{"key":"2083_CR7","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1101\/gad.1107303","volume":"17","author":"D Brancho","year":"2003","unstructured":"Brancho, D. et al. Mechanism of p38 MAP kinase activation in vivo. Genes Dev. 17, 1969\u20131978 (2003).","journal-title":"Genes Dev."},{"key":"2083_CR8","doi-asserted-by":"publisher","first-page":"55684","DOI":"10.18632\/oncotarget.18264","volume":"8","author":"I Corre","year":"2017","unstructured":"Corre, I., Paris, F. & Huot, J. The p38 pathway, a major pleiotropic cascade that transduces stress and metastatic signals in endothelial cells. Oncotarget 8, 55684\u201355714 (2017).","journal-title":"Oncotarget"},{"key":"2083_CR9","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.4161\/cc.4.9.2043","volume":"4","author":"PR Mittelstadt","year":"2005","unstructured":"Mittelstadt, P. R., Salvador, J. M., Fornace, A. J. & Ashwell, J. D. Activating p38 MAPK: new tricks for an old kinase. Cell Cycle 4, 1189\u20131192 (2005).","journal-title":"Cell Cycle"},{"key":"2083_CR10","doi-asserted-by":"publisher","unstructured":"Stramucci, L., Pranteda, A. & Bossi, G. Insights of crosstalk between p53 protein and the MKK3\/MKK6\/p38 MAPK signaling pathway in cancer. Cancers 10, https:\/\/doi.org\/10.3390\/cancers10050131(2018).","DOI":"10.3390\/cancers10050131"},{"key":"2083_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-60761-795-2_1","volume":"661","author":"Y Keshet","year":"2010","unstructured":"Keshet, Y. & Seger, R. The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol. Biol. 661, 3\u201338 (2010).","journal-title":"Methods Mol. Biol."},{"key":"2083_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fcell.2016.00031","volume":"4","author":"A Esc\u00f3s","year":"2016","unstructured":"Esc\u00f3s, A., Risco, A., Alsina-Beauchamp, D. & Cuenda, A. p38\u03b3 and p38\u03b4 mitogen activated protein kinases (MAPKs), new stars in the MAPK galaxy. Front. Cell Dev. Biol. 4, 31 (2016).","journal-title":"Front. Cell Dev. Biol."},{"key":"2083_CR13","doi-asserted-by":"publisher","first-page":"5267","DOI":"10.1038\/sj.onc.1210332","volume":"26","author":"MR Junttila","year":"2007","unstructured":"Junttila, M. R. et al. p38alpha and p38delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Oncogene 26, 5267\u20135279 (2007).","journal-title":"Oncogene"},{"key":"2083_CR14","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1128\/MCB.00784-13","volume":"33","author":"J Kwong","year":"2013","unstructured":"Kwong, J. et al. Induction of p38\u03b4 expression plays an essential role in oncogenic ras-induced senescence. Mol. Cell Biol. 33, 3780\u20133794 (2013).","journal-title":"Mol. Cell Biol."},{"key":"2083_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.semcancer.2004.04.006","volume":"14","author":"D Engelberg","year":"2004","unstructured":"Engelberg, D. Stress-activated protein kinases-tumor suppressors or tumor initiators? Semin. Cancer Biol. 14, 271\u2013282 (2004).","journal-title":"Semin. Cancer Biol."},{"key":"2083_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.canlet.2016.10.008","volume":"384","author":"X Zou","year":"2017","unstructured":"Zou, X. & Blank, M. Targeting p38 MAP kinase signaling in cancer through post-translational modifications. Cancer Lett. 384, 19\u201326 (2017).","journal-title":"Cancer Lett."},{"key":"2083_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.591","volume":"6","author":"S Baldari","year":"2015","unstructured":"Baldari, S., Ubertini, V., Garufi, A., D\u2019Orazi, G. & Bossi, G. Targeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications. Cell Death Dis. 6, e1621 (2015).","journal-title":"Cell Death Dis."},{"key":"2083_CR18","doi-asserted-by":"publisher","first-page":"14160","DOI":"10.1074\/jbc.M109.094813","volume":"285","author":"A Gurtner","year":"2010","unstructured":"Gurtner, A. et al. Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function. J. Biol. Chem. 285, 14160\u201314169 (2010).","journal-title":"J. Biol. Chem."},{"key":"2083_CR19","doi-asserted-by":"publisher","first-page":"e28406","DOI":"10.1371\/journal.pone.0028406","volume":"6","author":"EM Galan-Moya","year":"2011","unstructured":"Galan-Moya, E. M. et al. Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC. PLoS ONE 6, e28406 (2011).","journal-title":"PLoS ONE"},{"key":"2083_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1158\/0008-5472.CAN-13-1310","volume":"74","author":"AJ MacNeil","year":"2014","unstructured":"MacNeil, A. J. et al. MAPK kinase 3 is a tumor suppressor with reduced copy number in breast cancer. Cancer Res. 74, 162\u2013172 (2014).","journal-title":"Cancer Res."},{"key":"2083_CR21","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/sj.bjc.6605780","volume":"103","author":"K Bracht","year":"2010","unstructured":"Bracht, K., Nicholls, A. M., Liu, Y. & Bodmer, W. F. 5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency. Br. J. Cancer 103, 340\u2013346 (2010).","journal-title":"Br. J. Cancer"},{"key":"2083_CR22","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/onc.2011.321","volume":"31","author":"MA de la Cruz-Morcillo","year":"2012","unstructured":"de la Cruz-Morcillo, M. A. et al. P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance. Oncogene 31, 1073\u20131085 (2012).","journal-title":"Oncogene"},{"key":"2083_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1158\/1535-7163.MCT-11-0684","volume":"11","author":"MS Tsai","year":"2012","unstructured":"Tsai, M. S. et al. Inhibition of p38 MAPK-dependent excision repair cross-complementing 1 expression decreases the DNA repair capacity to sensitize lung cancer cells to etoposide. Mol. Cancer Ther. 11, 561\u2013571 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"2083_CR24","doi-asserted-by":"publisher","first-page":"8472","DOI":"10.1002\/jcb.27073","volume":"119","author":"JL Liu","year":"2018","unstructured":"Liu, J. L. et al. Effect of 5-fluorouracil on excision repair cross-complementing 1 expression and consequent cytotoxicity regulation in human gastric cancer cells. J. Cell. Biochem. 119, 8472\u20138480 (2018).","journal-title":"J. Cell. Biochem."},{"key":"2083_CR25","doi-asserted-by":"publisher","first-page":"pii: jcs216671","DOI":"10.1242\/jcs.216671","volume":"131","author":"C Zhang","year":"2018","unstructured":"Zhang, C., Gao, J., Li, M., Deng, Y. & Jiang, C. p38\u03b4 MAPK regulates aggresome biogenesis by phosphorylating SQSTM1 in response to proteasomal stress. J. Cell Sci. 131, pii: jcs216671 (2018).","journal-title":"J. Cell Sci."},{"key":"2083_CR26","doi-asserted-by":"publisher","first-page":"6150","DOI":"10.1158\/0008-5472.CAN-14-0870","volume":"74","author":"P Del Reino","year":"2014","unstructured":"Del Reino, P. et al. Pro-oncogenic role of alternative p38 mitogen-activated protein kinases p38\u03b3 and p38\u03b4, linking inflammation and cancer in colitis-associated colon cancer. Cancer Res. 74, 6150\u20136160 (2014).","journal-title":"Cancer Res."},{"key":"2083_CR27","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1038\/nsmb.2668","volume":"20","author":"GF DeNicola","year":"2013","unstructured":"DeNicola, G. F. et al. Mechanism and consequence of the autoactivation of p38\u03b1 mitogen-activated protein kinase promoted by TAB1. Nat. Struct. Mol. Biol. 20, 1182\u20131190 (2013).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2083_CR28","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.canlet.2013.10.035","volume":"344","author":"A Germani","year":"2014","unstructured":"Germani, A. et al. Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38\u03b1 modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A. Cancer Lett. 344, 110\u2013118 (2014).","journal-title":"Cancer Lett."},{"key":"2083_CR29","doi-asserted-by":"publisher","first-page":"6763","DOI":"10.1158\/0008-5472.CAN-05-3699","volume":"66","author":"N Giafis","year":"2006","unstructured":"Giafis, N. et al. Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res. 66, 6763\u20136771 (2006).","journal-title":"Cancer Res."},{"key":"2083_CR30","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.cellsig.2016.05.009","volume":"28","author":"HW Huth","year":"2016","unstructured":"Huth, H. W., Albarnaz, J. D., Torres, A. A., Bonjardim, C. A. & Ropert, C. MEK2 controls the activation of MKK3\/MKK6-p38 axis involved in the MDA-MB-231 breast cancer cell survival: correlation with cyclin D1 expression. Cell Signal. 28, 1283\u20131291 (2016).","journal-title":"Cell Signal."},{"key":"2083_CR31","doi-asserted-by":"publisher","first-page":"15149","DOI":"10.1074\/jbc.M110.105429","volume":"285","author":"M Loesch","year":"2010","unstructured":"Loesch, M. et al. p38gamma MAPK cooperates with c-Jun in trans-activating matrix metalloproteinase 9. J. Biol. Chem. 285, 15149\u201315158 (2010).","journal-title":"J. Biol. Chem."},{"key":"2083_CR32","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.bbrc.2011.02.083","volume":"406","author":"C Svensson","year":"2011","unstructured":"Svensson, C. et al. Pro-survival effects of JNK and p38 MAPK pathways in LPS-induced activation of BV-2 cells. Biochem. Biophys. Res. Commun. 406, 488\u2013492 (2011).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2083_CR33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1021\/cb700025j","volume":"2","author":"J Chen","year":"2007","unstructured":"Chen, J. et al. A fragment-based approach for the discovery of isoform-specific p38alpha inhibitors. ACS Chem. Biol. 2, 329\u2013336 (2007).","journal-title":"ACS Chem. Biol."},{"key":"2083_CR34","doi-asserted-by":"publisher","first-page":"19472","DOI":"10.1074\/jbc.M414221200","volume":"280","author":"Y Kuma","year":"2005","unstructured":"Kuma, Y. et al. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J. Biol. Chem. 280, 19472\u201319479 (2005).","journal-title":"J. Biol. Chem."},{"key":"2083_CR35","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1158\/1078-0432.CCR-15-1718","volume":"22","author":"A Patnaik","year":"2016","unstructured":"Patnaik, A. et al. A First-in-Human Phase I study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 dimesylate), in patients with advanced cancer. Clin. Cancer Res. 22, 1095\u20131102 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2083_CR36","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.tibs.2017.02.008","volume":"42","author":"A Cuenda","year":"2017","unstructured":"Cuenda, A. & Sanz-Ezquerro, J. J. p38\u03b3 and p38\u03b4: from spectators to key physiological players. Trends Biochem. Sci. 42, 431\u2013442 (2017).","journal-title":"Trends Biochem. Sci."},{"key":"2083_CR37","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1002\/art.34489","volume":"64","author":"M Guma","year":"2012","unstructured":"Guma, M. et al. Antiinflammatory functions of p38 in mouse models of rheumatoid arthritis: advantages of targeting upstream kinases MKK-3 or MKK-6. Arthritis Rheum. 64, 2887\u20132895 (2012).","journal-title":"Arthritis Rheum."},{"key":"2083_CR38","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.bmcl.2015.11.054","volume":"26","author":"M Adams","year":"2016","unstructured":"Adams, M. et al. Fragment-based drug discovery of potent and selective MKK3\/6 inhibitors. Bioorg. Med. Chem. Lett. 26, 1086\u20131089 (2016).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2083_CR39","doi-asserted-by":"publisher","first-page":"370","DOI":"10.6004\/jnccn.2017.0036","volume":"15","author":"AB Benson","year":"2017","unstructured":"Benson, A. B. et al. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 15, 370\u2013398 (2017).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"2083_CR40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1128\/JCM.40.1.105-110.2002","volume":"40","author":"T Yoshida","year":"2002","unstructured":"Yoshida, T., Maeda, S., Deguchi, T. & Ishiko, H. Phylogeny-based rapid identification of mycoplasmas and ureaplasmas from urethritis patients. J. Clin. Microbiol. 40, 105\u2013110 (2002).","journal-title":"J. Clin. Microbiol."},{"key":"2083_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0014-5793(97)00021-5","volume":"403","author":"J Han","year":"1997","unstructured":"Han, J., Wang, X., Jiang, Y., Ulevitch, R. J. & Lin, S. Identification and characterization of a predominant isoform of human MKK3. FEBS Lett. 403, 19\u201322 (1997).","journal-title":"FEBS Lett."},{"key":"2083_CR42","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00428-017-2276-y","volume":"472","author":"L Bertero","year":"2018","unstructured":"Bertero, L. et al. Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria\u2014what has changed and why? Virchows Arch. 472, 519\u2013531 (2018).","journal-title":"Virchows Arch."},{"key":"2083_CR43","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.7717\/peerj-cs.67","volume":"2","author":"J Anaya","year":"2016","unstructured":"Anaya, J. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Comput. Sci. 2, e67 (2016).","journal-title":"PeerJ Comput. Sci."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-2083-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-2083-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-2083-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T17:47:44Z","timestamp":1671212864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-2083-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":43,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11]]}},"alternative-id":["2083"],"URL":"https:\/\/doi.org\/10.1038\/s41419-019-2083-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,6]]},"assertion":[{"value":"15 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"842"}}